Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
MASH
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Advertisement
Advertisement
Trending on AJMC
1
Olanzapine/Samidorphan Tied to Longer Persistence in Schizophrenia
2
Medicare Plan Terminations Hit 4.3 Million as Part D Market Shrinks
3
At the Pharmacy, Affordability Connects Policy, Plans, and Patients
4
The DTC GLP-1 Boom Solved Access. Can It Solve Adherence?
5